vs
Side-by-side financial comparison of LXP Industrial Trust (LXP) and Syndax Pharmaceuticals Inc (SNDX). Click either name above to swap in a different company.
LXP Industrial Trust is the larger business by last-quarter revenue ($86.7M vs $68.5M, roughly 1.3× Syndax Pharmaceuticals Inc). LXP Industrial Trust runs the higher net margin — 33.2% vs -99.3%, a 132.5% gap on every dollar of revenue. On growth, Syndax Pharmaceuticals Inc posted the faster year-over-year revenue change (791.7% vs -14.0%).
LXP Industrial Trust is a publicly traded real estate investment trust (REIT) that owns, operates, and invests in high-quality industrial real estate assets, primarily distribution centers, logistics facilities, and light industrial properties across key markets in the United States. Its tenant base covers e-commerce, third-party logistics, and advanced manufacturing sectors, delivering stable long-term returns for its investors.
Syndax Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oncology therapies for patients with hard-to-treat cancers. Its pipeline includes targeted and immunotherapy candidates addressing unmet medical needs, primarily serving global oncology healthcare stakeholders and patient populations.
LXP vs SNDX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.7M | $68.5M |
| Net Profit | $28.8M | $-68.0M |
| Gross Margin | 81.5% | — |
| Operating Margin | 34.6% | -91.3% |
| Net Margin | 33.2% | -99.3% |
| Revenue YoY | -14.0% | 791.7% |
| Net Profit YoY | — | 27.8% |
| EPS (diluted) | — | $-0.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.7M | $68.5M | ||
| Q3 25 | $86.9M | $45.9M | ||
| Q2 25 | $87.7M | $38.0M | ||
| Q1 25 | $88.9M | $20.0M | ||
| Q4 24 | $100.9M | — | ||
| Q3 24 | $85.6M | $12.5M | ||
| Q2 24 | $85.8M | — | ||
| Q1 24 | $86.3M | $0 |
| Q4 25 | $28.8M | $-68.0M | ||
| Q3 25 | $36.3M | $-60.7M | ||
| Q2 25 | $29.1M | $-71.8M | ||
| Q1 25 | $19.0M | $-84.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $6.3M | $-84.1M | ||
| Q2 24 | $5.4M | — | ||
| Q1 24 | $-269.0K | $-72.4M |
| Q4 25 | 81.5% | — | ||
| Q3 25 | 82.3% | — | ||
| Q2 25 | 81.9% | — | ||
| Q1 25 | 80.7% | — | ||
| Q4 24 | 85.3% | — | ||
| Q3 24 | 82.5% | — | ||
| Q2 24 | 82.0% | — | ||
| Q1 24 | 82.4% | — |
| Q4 25 | 34.6% | -91.3% | ||
| Q3 25 | 50.4% | -125.2% | ||
| Q2 25 | 33.7% | -182.7% | ||
| Q1 25 | 21.8% | -417.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | 7.9% | -716.6% | ||
| Q2 24 | 6.9% | — | ||
| Q1 24 | 1.0% | — |
| Q4 25 | 33.2% | -99.3% | ||
| Q3 25 | 41.7% | -132.4% | ||
| Q2 25 | 33.2% | -189.3% | ||
| Q1 25 | 21.4% | -423.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | 7.4% | -673.0% | ||
| Q2 24 | 6.3% | — | ||
| Q1 24 | -0.3% | — |
| Q4 25 | — | $-0.78 | ||
| Q3 25 | $0.12 | $-0.70 | ||
| Q2 25 | $0.09 | $-0.83 | ||
| Q1 25 | $0.06 | $-0.98 | ||
| Q4 24 | — | — | ||
| Q3 24 | $0.02 | $-0.98 | ||
| Q2 24 | $0.01 | — | ||
| Q1 24 | $-0.01 | $-0.85 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $170.4M | $394.1M |
| Total DebtLower is stronger | $1.4B | — |
| Stockholders' EquityBook value | $2.0B | $64.6M |
| Total Assets | $3.5B | $529.7M |
| Debt / EquityLower = less leverage | 0.66× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $170.4M | $394.1M | ||
| Q3 25 | $229.7M | $436.0M | ||
| Q2 25 | $71.0M | $455.2M | ||
| Q1 25 | $70.9M | $512.2M | ||
| Q4 24 | $101.8M | — | ||
| Q3 24 | $55.0M | $389.6M | ||
| Q2 24 | $48.7M | — | ||
| Q1 24 | $293.8M | $434.6M |
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $2.0B | $64.6M | ||
| Q3 25 | $2.1B | $115.4M | ||
| Q2 25 | $2.1B | $157.4M | ||
| Q1 25 | $2.1B | $215.1M | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.1B | $366.4M | ||
| Q2 24 | $2.1B | — | ||
| Q1 24 | $2.2B | $491.9M |
| Q4 25 | $3.5B | $529.7M | ||
| Q3 25 | $3.7B | $551.8M | ||
| Q2 25 | $3.7B | $596.1M | ||
| Q1 25 | $3.8B | $640.7M | ||
| Q4 24 | $3.8B | — | ||
| Q3 24 | $3.9B | $425.8M | ||
| Q2 24 | $3.9B | — | ||
| Q1 24 | $4.2B | $543.0M |
| Q4 25 | 0.66× | — | ||
| Q3 25 | 0.72× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $188.7M | $-69.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 6.56× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $188.7M | $-69.5M | ||
| Q3 25 | $63.5M | $-70.5M | ||
| Q2 25 | $44.3M | $-87.8M | ||
| Q1 25 | $39.0M | $-95.2M | ||
| Q4 24 | $211.2M | — | ||
| Q3 24 | $64.6M | $-62.3M | ||
| Q2 24 | $38.5M | — | ||
| Q1 24 | $38.9M | $-83.5M |
| Q4 25 | 6.56× | — | ||
| Q3 25 | 1.75× | — | ||
| Q2 25 | 1.52× | — | ||
| Q1 25 | 2.05× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.18× | — | ||
| Q2 24 | 7.09× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
